Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib-Reference-Cited by-同舟云学术

Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib

Published:2021-10-15 Issue:20 Volume:60 Page:3305-3308
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Koshiishi Megumi¹,Odate Toru²,Nakagawa Yukie¹,Suzuki Jun¹,Kumagai Takuya¹,Kawashima Ichiro¹,Yamamoto Takeo¹,Nakajima Kei¹,Tanaka Masaru¹,Oishi Naoki²,Kondo Tetuso²,Kirito Keita¹

Affiliation:

1. Department of Hematology/Oncology, University of Yamanashi, Japan

2. Department of Pathology, University of Yamanashi, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/60/20/60_6979-20/_pdf

Reference17 articles.

1. 1. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369: 32-42, 2013.

2. 2. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373: 2425-2437, 2015.

3. 3. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1: 80-87, 2015.

4. 4. Iskierka-Jażdżewska E, Puła B, Szeremet A, et al. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: a report from the Polish Adult Leukemia Study Group (PALG). Adv Clin Exp Med 28: 1051-1057, 2019.

5. 5. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129: 1469-1479, 2017.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hodgkin's variant of Richter transformation during ibrutinib therapy: A case report and review of the literature;Clinical Case Reports;2022-10